AU2023211719A1 - Ntsr1-targeted radiopharmaceuticals and dna damage response inhibitor combination therapy - Google Patents

Ntsr1-targeted radiopharmaceuticals and dna damage response inhibitor combination therapy Download PDF

Info

Publication number
AU2023211719A1
AU2023211719A1 AU2023211719A AU2023211719A AU2023211719A1 AU 2023211719 A1 AU2023211719 A1 AU 2023211719A1 AU 2023211719 A AU2023211719 A AU 2023211719A AU 2023211719 A AU2023211719 A AU 2023211719A AU 2023211719 A1 AU2023211719 A1 AU 2023211719A1
Authority
AU
Australia
Prior art keywords
mammal
group
radiopharmaceutical
alkyl
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023211719A
Other languages
English (en)
Inventor
John R. Forbes
Saleemulla MAHAMMAD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fusion Pharmaceuticals Inc
Original Assignee
Fusion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fusion Pharmaceuticals Inc filed Critical Fusion Pharmaceuticals Inc
Publication of AU2023211719A1 publication Critical patent/AU2023211719A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2023211719A 2022-01-28 2023-01-27 Ntsr1-targeted radiopharmaceuticals and dna damage response inhibitor combination therapy Pending AU2023211719A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263304178P 2022-01-28 2022-01-28
US63/304,178 2022-01-28
PCT/CA2023/050108 WO2023141717A1 (en) 2022-01-28 2023-01-27 Ntsr1-targeted radiopharmaceuticals and dna damage response inhibitor combination therapy

Publications (1)

Publication Number Publication Date
AU2023211719A1 true AU2023211719A1 (en) 2024-08-15

Family

ID=87469883

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023211719A Pending AU2023211719A1 (en) 2022-01-28 2023-01-27 Ntsr1-targeted radiopharmaceuticals and dna damage response inhibitor combination therapy

Country Status (12)

Country Link
US (1) US20250177581A1 (cg-RX-API-DMAC10.html)
EP (1) EP4469092A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025503215A (cg-RX-API-DMAC10.html)
KR (1) KR20240142499A (cg-RX-API-DMAC10.html)
CN (1) CN119136846A (cg-RX-API-DMAC10.html)
AR (1) AR128382A1 (cg-RX-API-DMAC10.html)
AU (1) AU2023211719A1 (cg-RX-API-DMAC10.html)
CA (1) CA3249955A1 (cg-RX-API-DMAC10.html)
IL (1) IL314530A (cg-RX-API-DMAC10.html)
MX (1) MX2024009312A (cg-RX-API-DMAC10.html)
TW (1) TW202337451A (cg-RX-API-DMAC10.html)
WO (1) WO2023141717A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4355325A4 (en) * 2021-06-16 2025-05-07 Fusion Pharmaceuticals Inc. COMBINATION OF A NEUROTENSIN RECEPTOR-BINDING COMPOUND AND FOLFIRINOX

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2478695B1 (es) * 2012-12-20 2015-04-28 Servicio Andaluz De Salud Dispositivo para inducir hipotermia terapéutica
KR20210099073A (ko) * 2018-12-03 2021-08-11 퓨전 파마슈티칼즈 인크. 방사성면역접합체와 체크포인트 억제제의 조합 요법

Also Published As

Publication number Publication date
EP4469092A1 (en) 2024-12-04
JP2025503215A (ja) 2025-01-30
TW202337451A (zh) 2023-10-01
MX2024009312A (es) 2024-08-06
US20250177581A1 (en) 2025-06-05
CA3249955A1 (en) 2023-08-03
KR20240142499A (ko) 2024-09-30
WO2023141717A1 (en) 2023-08-03
CN119136846A (zh) 2024-12-13
AR128382A1 (es) 2024-04-24
IL314530A (en) 2024-09-01

Similar Documents

Publication Publication Date Title
JP7013369B2 (ja) Ezh2阻害剤により卵巣の悪性ラブドイド腫瘍(mrto)/高カルシウム血症型の卵巣の小細胞癌(sccoht)を処置するための方法
JP2025013486A (ja) 放射性免疫複合体とdnaの損傷および修復阻害剤の併用療法
CN105792847B (zh) 急性骨髓性白血病(aml)的新型组合治疗
EA020466B1 (ru) Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
ES3055488T3 (en) Tegavivint for use in the treatment of pulmonary fibrosis
EP3787631B1 (en) Modulators of orphan nuclear receptors for nash and other metabolic disorders
AU2023210698A1 (en) Psma-targeted radiopharmaceuticals and checkpoint inhibitor combination therapy
EP4469092A1 (en) Ntsr1-targeted radiopharmaceuticals and dna damage response inhibitor combination therapy
EP4469093A1 (en) Ntsr1-targeted radiopharmaceuticals and checkpoint inhibitor combination therapy
WO2024211998A1 (en) Psma-targeted radiopharmaceuticals and dna damage response inhibitor combination therapy
WO2023164777A1 (en) Gucy2c-targeted radiopharmaceuticals and use thereof
CN101282728A (zh) 有机化合物的组合
WO2025019952A1 (en) Psma-targeted radiopharmaceuticals for treatment of cancer
HK40060346A (en) Radioimmunoconjugates and dna damage and repair inhibitor combination therapy
HK1222808B (en) Novel combination treatment for acute myeloid leukemia (aml)